(LH) Laboratory of America - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5049221055

Diagnostics, Testing, Lab, Drug, Health

Stock: Health Care Services
Age 35.8y

MCap 22,509m
Avg Vol 658K (169M USD)

Beta 0.599
Volatility 21.24%

EPS (Earnings per Share)

EPS CAGR: -52.99%
EPS Trend: -53.4%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: -3.39%
Rev. Trend: -4.8%

Last SUE: 0.09
Qual. Beats: 0

Dividends

Dividend Yield	1.11%
Yield on Cost 5y	1.95%
Yield CAGR 5y	15.77%
Payout Consistency	16.0%
Payout Ratio	18.2%

Risk via 5d forecast
Volatility	21.2%
Value at Risk 5%th	32.9%
Relative Tail Risk	-5.83%

Reward TTM
Sharpe Ratio	0.44
Alpha	0.89
CAGR/Max DD	0.50

Character TTM
Hurst Exponent	0.502
Beta	0.599
Beta Downside	0.570

Drawdowns 3y
Max DD	17.36%
Mean DD	6.40%
Median DD	6.14%

Description: LH Laboratory of America December 17, 2025

Labcorp (NYSE: LH) operates two primary segments-Diagnostics Laboratories and Biopharma Laboratory Services-delivering a broad portfolio that ranges from routine blood chemistry and urinalysis to high-complexity gene-based and esoteric tests, anatomic pathology, pharmacogenetics, and companion-diagnostic development. The company also offers digital platforms for patients and providers, specimen-collection logistics, and drug-development support services, serving a client base that includes pharma/biotech firms, MCOs, hospitals, and agricultural chemical companies.

Key recent metrics underscore the business’s scale and growth trajectory: FY 2023 revenue reached $13.9 billion, with a 7 % year-over-year increase driven largely by specialty-testing volumes and higher-margin biopharma services; operating margin improved to 9.2 % as the firm leveraged automation and digital front-end tools. Core sector drivers include the accelerating adoption of molecular diagnostics (projected CAGR ≈ 12 % through 2028) and sustained reimbursement pressure from Medicare policy reforms, which together shape pricing power and test-mix profitability.

For a deeper quantitative assessment, you may explore ValueRay’s detailed LH valuation model.

Piotroski VR‑10 (Strict, 0-10) 9.0

Net Income: 855.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.08 > 0.02 and ΔFCF/TA 3.03 > 1.0
NWC/Revenue: 10.53% < 20% (prev 11.78%; Δ -1.25% < -1%)
CFO/TA 0.10 > 3% & CFO 1.80b > Net Income 855.2m
Net Debt (5.93b) to EBITDA (2.01b): 2.95 < 3
Current Ratio: 1.55 > 1.5 & < 3
Outstanding Shares: last quarter (83.7m) vs 12m ago -0.83% < -2%
Gross Margin: 28.45% > 18% (prev 0.28%; Δ 2817 % > 0.5%)
Asset Turnover: 74.66% > 50% (prev 68.30%; Δ 6.36% > 0%)
Interest Coverage Ratio: 5.73 > 6 (EBITDA TTM 2.01b / Interest Expense TTM 232.5m)

Altman Z'' 3.51

A: 0.08 (Total Current Assets 4.08b - Total Current Liabilities 2.63b) / Total Assets 18.26b
B: 0.48 (Retained Earnings 8.70b / Total Assets 18.26b)
C: 0.07 (EBIT TTM 1.33b / Avg Total Assets 18.44b)
D: 0.91 (Book Value of Equity 8.66b / Total Liabilities 9.55b)
Altman-Z'' Score: 3.51 = A

Beneish M -3.05

DSRI: 0.94 (Receivables 2.27b/2.22b, Revenue 13.77b/12.71b)
GMI: 0.98 (GM 28.45% / 27.92%)
AQI: 1.06 (AQ_t 0.61 / AQ_t-1 0.57)
SGI: 1.08 (Revenue 13.77b / 12.71b)
TATA: -0.05 (NI 855.2m - CFO 1.80b) / TA 18.26b)
Beneish M-Score: -3.05 = AA

ValueRay F-Score (Strict, 0-100) 58.37

1. Piotroski: 9.0pt
2. FCF Yield: 4.85%
3. FCF Margin: 10.03%
4. Debt/Equity: 0.75
5. Debt/Ebitda: 2.95
6. ROIC - WACC: 0.87%
7. RoE: 10.20%
8. Revenue Trend: -4.84%
9. EPS Trend: -53.43%

What is the price of LH shares?

As of January 23, 2026, the stock is trading at USD 269.97 with a total of 735,309 shares traded.
Over the past week, the price has changed by +0.40%, over one month by +5.85%, over three months by -4.29% and over the past year by +12.59%.

Is LH a buy, sell or hold?

Laboratory of America has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy LH.

Strong Buy: 13
Buy: 3
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the LH price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	300.1	11.1%
Analysts Target Price	300.1	11.1%
ValueRay Target Price	286.1	6%

LH Fundamental Data Overview January 21, 2026

P/E Trailing = 26.6081
P/E Forward = 15.2905
P/S = 1.6352
P/B = 2.582
P/EG = 1.9838
Revenue TTM = 13.77b USD
EBIT TTM = 1.33b USD
EBITDA TTM = 2.01b USD
Long Term Debt = 5.08b USD (from longTermDebt, last quarter)
Short Term Debt = 691.1m USD (from shortTermDebt, last quarter)
Debt = 6.53b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.93b USD (from netDebt column, last quarter)
Enterprise Value = 28.44b USD (22.51b + Debt 6.53b - CCE 598.1m)
Interest Coverage Ratio = 5.73 (Ebit TTM 1.33b / Interest Expense TTM 232.5m)
EV/FCF = 20.60x (Enterprise Value 28.44b / FCF TTM 1.38b)
FCF Yield = 4.85% (FCF TTM 1.38b / Enterprise Value 28.44b)
FCF Margin = 10.03% (FCF TTM 1.38b / Revenue TTM 13.77b)
Net Margin = 6.21% (Net Income TTM 855.2m / Revenue TTM 13.77b)
Gross Margin = 28.45% ((Revenue TTM 13.77b - Cost of Revenue TTM 9.85b) / Revenue TTM)
Gross Margin QoQ = 28.77% (prev 29.66%)
Tobins Q-Ratio = 1.56 (Enterprise Value 28.44b / Total Assets 18.26b)
Interest Expense / Debt = 0.86% (Interest Expense 56.0m / Debt 6.53b)
Taxrate = 22.40% (75.5m / 337.0m)
NOPAT = 1.03b (EBIT 1.33b * (1 - 22.40%))
Current Ratio = 1.55 (Total Current Assets 4.08b / Total Current Liabilities 2.63b)
Debt / Equity = 0.75 (Debt 6.53b / totalStockholderEquity, last quarter 8.70b)
Debt / EBITDA = 2.95 (Net Debt 5.93b / EBITDA 2.01b)
Debt / FCF = 4.30 (Net Debt 5.93b / FCF TTM 1.38b)
Total Stockholder Equity = 8.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.64% (Net Income 855.2m / Total Assets 18.26b)
RoE = 10.20% (Net Income TTM 855.2m / Total Stockholder Equity 8.38b)
RoCE = 9.90% (EBIT 1.33b / Capital Employed (Equity 8.38b + L.T.Debt 5.08b))
RoIC = 7.31% (NOPAT 1.03b / Invested Capital 14.15b)
WACC = 6.44% (E(22.51b)/V(29.04b) * Re(8.12%) + D(6.53b)/V(29.04b) * Rd(0.86%) * (1-Tc(0.22)))
Discount Rate = 8.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.71%
[DCF Debug] Terminal Value 80.84% ; FCFF base≈1.17b ; Y1≈910.9m ; Y5≈588.9m
Fair Price DCF = 115.2 (EV 15.48b - Net Debt 5.93b = Equity 9.55b / Shares 82.9m; r=6.44% [WACC]; 5y FCF grow -26.04% → 2.90% )
EPS Correlation: -53.43 | EPS CAGR: -52.99% | SUE: -4.0 | # QB: 0
Revenue Correlation: -4.84 | Revenue CAGR: -3.39% | SUE: 0.09 | # QB: 0
EPS next Quarter (2026-03-31): EPS=4.11 | Chg30d=+0.006 | Revisions Net=-1 | Analysts=14
EPS next Year (2026-12-31): EPS=17.52 | Chg30d=-0.009 | Revisions Net=-2 | Growth EPS=+7.3% | Growth Revenue=+4.5%

Additional Sources for LH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle